The KEYNOTE-048 study led to the approval of pembrolizumab as monotherapy or in combination with chemotherapy with platinum and 5-fluorouracil (5-FU) for first-line treatment for PD-L1-positive R/M HNSCC with CPS ≥ 1 (9). This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.